Liposomal Monobenzone as a Potential Therapy for Melanoma: A Systematic Review

Abstract

Topical Monobenzone, a potent melanocytotoxic drug due to its ability to inhibit
enzyme tyrosinase and induce immune response against melanocytes, is approved
for permanent depigmentation of skin in untreatable vitiligo patients. Its liposomal
formulation when administered systemically in preclinical studies done on mice and
in vitro melanoma cell lines had shown strong anti-melanoma effect with minimal
adverse effects to host and non melanocytes. This study reviews the potential of
liposomal monobenzone for treatment of Melanoma and compares its potential with
topical Monobenzone with topical Imiquimod for treatment of Melanoma and
recommends further research on potential of liposomal Monobenzone for treatment
of melanoma.